source
- Kyorin signs $140M deal for Japan rights to Edesa's ARDS antibodyKyorin Pharmaceutical will pay $12 million up front and up to $134 million in milestones, plus royalties, for exclusive Japan rights to Edesa Biotech’s anti‑TLR4 antibody, paridiprubart, intended f…
- Pentagon removes WuXi AppTec from Chinese military companies list, but risk of redesignation remainsThe U.S. Department of Defense announced that WuXi AppTec, a Shanghai-based contract research and manufacturing firm, has been taken off the Pentagon’s list of Chinese entities tied to the People’s…